西罗莫司联合索拉非尼治疗肝移植后 HCC 复发：病例报告。
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
机构信息
Division of Hematology and Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, United States.
出版信息
World J Gastroenterol. 2010 Nov 21;16(43):5518-22. doi: 10.3748/wjg.v16.i43.5518.
Abstract
A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.
摘要
本报告介绍了一例肝癌（HCC）患者，该患者在 HCC 肝移植后出现肺部复发。该患者在索拉非尼治疗期间疾病进展，通过计算机断层扫描（CT）以及连续的血清甲胎蛋白（AFP）升高显示。在他的免疫抑制治疗成功转换为西罗莫司并继续使用索拉非尼后，根据 RECIST 标准，他达到部分缓解，AFP 恢复正常。雷帕霉素靶蛋白抑制剂（mTORI），包括西罗莫司单药或与索拉非尼联合使用，可能对移植后 HCC 的治疗有效。
相似文献
1
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.西罗莫司联合索拉非尼治疗肝移植后 HCC 复发：病例报告。
World J Gastroenterol. 2010 Nov 21;16(43):5518-22. doi: 10.3748/wjg.v16.i43.5518.
2
Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.西罗莫司和索拉非尼治疗原位肝移植后复发的肝细胞癌患者实现放射学完全缓解
J Gastrointest Cancer. 2011 Mar;42(1):50-3. doi: 10.1007/s12029-010-9196-2.
3
Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.索拉非尼治疗肝移植受者单发转移性肺病变的明显缓解。
Am J Transplant. 2009 Dec;9(12):2851-4. doi: 10.1111/j.1600-6143.2009.02860.x.
4
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.索拉非尼联合哺乳动物雷帕霉素靶蛋白抑制剂治疗肝移植后复发性肝细胞癌的疗效和安全性。
Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434.
5
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.肝细胞癌与肝移植：分子靶向策略的临床视角
Med Mol Morphol. 2011 Sep;44(3):117-24. doi: 10.1007/s00795-011-0547-2. Epub 2011 Sep 16.
6
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.肝移植前肝细胞癌患者的索拉非尼治疗
Hepatology. 2010 Sep;52(3):1171-2. doi: 10.1002/hep.23702.
7
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.活体肝移植后肝细胞癌复发患者的临床分析
World J Gastroenterol. 2016 Jul 7;22(25):5790-9. doi: 10.3748/wjg.v22.i25.5790.
8
Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.索拉非尼在肝切除术后复发肝细胞癌患者行挽救性肝移植中的安全应用。
Med Oncol. 2011 Dec;28(4):1044-7. doi: 10.1007/s12032-010-9625-x. Epub 2010 Jul 16.
9
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.索拉非尼治疗肝移植后肝细胞癌复发。
Dig Liver Dis. 2012 May;44(5):432-7. doi: 10.1016/j.dld.2011.12.009. Epub 2012 Jan 20.
10
Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.索拉非尼治疗伴多发肺转移的晚期肝细胞癌完全缓解 1 例报告
Oncology. 2011;81 Suppl 1:152-7. doi: 10.1159/000333279. Epub 2011 Dec 22.
引用本文的文献
1
PathSynergy: a deep learning model for predicting drug synergy in liver cancer.PathSynergy：一种用于预测肝癌药物协同作用的深度学习模型。
Brief Bioinform. 2025 Mar 4;26(2). doi: 10.1093/bib/bbaf192.
2
Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT).肝移植肿瘤学中的免疫抑制：意大利肝移植专家委员会（I-BELT）立场文件。
Updates Surg. 2024 Jun;76(3):725-741. doi: 10.1007/s13304-024-01845-z. Epub 2024 May 7.
3
Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation.肝移植后肝细胞癌复发的管理
Cancers (Basel). 2021 Sep 29;13(19):4882. doi: 10.3390/cancers13194882.
4
Is the era of sorafenib over? A review of the literature.索拉非尼时代结束了吗？文献综述。
Ther Adv Med Oncol. 2020 May 26;12:1758835920927602. doi: 10.1177/1758835920927602. eCollection 2020.
5
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.基于索拉非尼的联合分子靶向治疗肝细胞癌
World J Gastroenterol. 2015 Nov 14;21(42):12059-70. doi: 10.3748/wjg.v21.i42.12059.
6
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.肝移植术后复发性肝细胞癌的管理：一项系统综述。
World J Gastroenterol. 2015 Oct 21;21(39):11185-98. doi: 10.3748/wjg.v21.i39.11185.
7
Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.晚期肝细胞癌患者的当前及未来治疗策略：mTOR抑制的作用
Liver Cancer. 2012 Nov;1(3-4):247-56. doi: 10.1159/000343839.
8
Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.通过 PDGFRβ 依赖性反馈环激活 PI3K/AKT 和 MAPK 通路参与肝癌对雷帕霉素的耐药性。
PLoS One. 2012;7(3):e33379. doi: 10.1371/journal.pone.0033379. Epub 2012 Mar 9.
9
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.肝细胞癌与肝移植：分子靶向策略的临床视角
Med Mol Morphol. 2011 Sep;44(3):117-24. doi: 10.1007/s00795-011-0547-2. Epub 2011 Sep 16.
10
Role of organ transplantation in the treatment of malignancies: hepatocellular carcinoma as the most common tumour treated with transplantation.器官移植在恶性肿瘤治疗中的作用：肝细胞癌是最常通过移植治疗的肿瘤。
Pathol Oncol Res. 2012 Jan;18(1):1-10. doi: 10.1007/s12253-011-9441-4. Epub 2011 Sep 7.
本文引用的文献
1
Liver transplantation for hepatocellular carcinoma: the Kyoto experience.肝移植治疗肝细胞癌：京都经验。
J Hepatobiliary Pancreat Sci. 2010 Sep;17(5):527-32. doi: 10.1007/s00534-009-0162-y. Epub 2009 Aug 26.
2
The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.mTOR 通路与人类肝细胞癌的不良预后相关。
Med Oncol. 2010 Jun;27(2):255-61. doi: 10.1007/s12032-009-9201-4. Epub 2009 Mar 20.
3
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.索拉非尼和雷帕霉素抑制肝癌小鼠模型的生长。
J Cell Mol Med. 2009 Aug;13(8B):2673-2683. doi: 10.1111/j.1582-4934.2009.00692.x. Epub 2009 Feb 9.
4
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.PI3K/PTEN/AKT/mTOR 通路在肝癌侵袭转移中的作用：与 MMP-9 的关系。
Hepatol Res. 2009 Feb;39(2):177-86. doi: 10.1111/j.1872-034X.2008.00449.x.
5
Sirolimus therapy in liver transplant patients: an initial experience at a single center.西罗莫司在肝移植患者中的治疗：单中心的初步经验。
Transplant Proc. 2008 Jul-Aug;40(6):1950-2. doi: 10.1016/j.transproceed.2008.05.005.
6
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
7
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.RAD001（依维莫司）在人肝细胞癌异种移植模型中抑制肿瘤生长。
J Cell Mol Med. 2009 Jul;13(7):1371-80. doi: 10.1111/j.1582-4934.2008.00364.x. Epub 2008 May 7.
8
Systemic therapy for hepatocellular carcinoma.肝细胞癌的全身治疗
Cancer J. 2008 Mar-Apr;14(2):123-7. doi: 10.1097/PPO.0b013e31816a6058.
9
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
Int J Clin Oncol. 2008 Feb;13(1):66-70. doi: 10.1007/s10147-007-0733-3. Epub 2008 Feb 29.
10
Epidemiology of hepatocellular carcinoma in Hispanics in the United States.美国西班牙裔人群肝细胞癌的流行病学
Arch Intern Med. 2007 Oct 8;167(18):1983-9. doi: 10.1001/archinte.167.18.1983.
Zotero 插件